TCR² Therapeutics to Participate in Two Upcoming Conferences in June
26 mai 2021 06h45 HE
|
TCR2 Therapeutics
CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from...
TCR² Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
13 mai 2021 06h45 HE
|
TCR2 Therapeutics
CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from...
TCR² Therapeutics to Present at the Truist Securities Life Sciences Summit
29 avr. 2021 06h45 HE
|
TCR2 Therapeutics
CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering...
TCR² Highlights Gavo-cel Translational Data and Emerging Solid Tumor Pipeline Preclinical Data at AACR Annual Meeting
10 avr. 2021 08h31 HE
|
TCR2 Therapeutics
CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering...
TCR² Therapeutics to Present at the Needham Healthcare Conference
08 avr. 2021 06h45 HE
|
TCR2 Therapeutics
CAMBRIDGE, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering...
TCR² Therapeutics Establishes Commercial-Scale Cell Therapy Manufacturing Facility
29 mars 2021 08h00 HE
|
TCR2 Therapeutics
85,000 square foot state-of-the-art facility being built in Rockville, MarylandAccelerates TCR2’s commercial-scale manufacturing timelines with production anticipated in 2023Aaron Vernon hired as Vice...
TCR² Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
11 mars 2021 06h45 HE
|
TCR2 Therapeutics
- Preliminary safety, efficacy and translational data from gavo-cel Phase 1 trial at AACR 2021 - Preclinical data on autologous CD70 and allogeneic mesothelin TRuC data at AACR 2021 ...
TCR² Presentations at American Association of Cancer Research (AACR) Annual Meeting 2021 to Highlight Solid Tumor Pipeline
10 mars 2021 16h45 HE
|
TCR2 Therapeutics
CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering...
TCR² Therapeutics to Participate in Two Upcoming Conferences in March
03 mars 2021 08h00 HE
|
TCR2 Therapeutics
CAMBRIDGE, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering...
TCR² Therapeutics to Present at SVB Leerink Global Healthcare Conference
17 févr. 2021 08h00 HE
|
TCR2 Therapeutics
CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering...